LONDON: GSK announced on Tuesday that it is investigating whether its best-selling shingles vaccine reduces the risk of dementia in a sample of over a million older persons in the UK.
The British pharmaceutical company is utilizing the medical records of approximately 1.4 million individuals between the ages of 65 and 66, some of whom had the Shingrix injection and others who did not.
According to Tony Wood, chief scientific officer at GSK, the data, which comes from the vast database of the state-run National Health Service (NHS), is a unique collection of information because a change in the UK’s shingles vaccination program has resulted in a naturally randomised study that is currently underway.
In 2023, the Shingrix vaccine was made available to people 65 and older as part of the expansion of the national vaccination program.
